X
Amgen and UCB re-file Evenity for US approval
https://pharmaphorum.com/news/amgen-ucb-evenity-fda-filing/
osteoporosis
Amgen/UCB’s osteoporosis drug hit by cardio risk
Competitor to Amgen’s Epogen also moves closer to market
Amgen/UCB reveal new osteoporosis drug data
But romosozumab missed secondary endpoint of non-vertebral fractures
Merck & Co. drops osteoporosis drug
Move boosts Amgen and UCB, which are developing a rival.
Amgen’s Prolia succeeds in glucocorticoid-induced osteoporosis
Possible new use for well-established drug.
UCB: growing sales and growing bones
The specialist pharma company is set to expand into osteoporosis through its partnership with Amgen
